A small interfering RNA (siRNA) therapy that silences hepatic PCSK9 mRNA, reducing PCSK9 protein production at the source rather than blocking the circulating protein. Results in sustained LDL-C reduction of ~50% with twice-yearly dosing after initial doses. FDA-approved as adjunct to diet and maximally tolerated statin for LDL-C lowering.
Dosing Notes
Initial dose, then 3 months later, then every 6 months — 284 mg subcutaneous injection. Convenience advantage over monthly injectables.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
Moderate ConfidenceSupported by limited controlled studies or consistent case series
Pooled ORION-9, -10, -11 analysis: inclisiran lowered LDL-C by average 50.6% from baseline with twice-yearly dosing and was associated with 26% lower probability of MACE. FDA-approved as adjunct to diet and maximally tolerated statin.
Verified Jul 2026
Peer Reviewed
Inclisiran: harnessing RNA interference for cholesterol lowering (JAHA)